54-97-7

Basic information

• Product Name: 2-Phenylcyclopropane-1-amine
• Synonyms: 1-Amino-2-phenylcyclopropane;2-Phenylcyclopropane-1-amine;2-Phenylcyclopropylamine;2-Phenylcyclopropan-1-amine;Cyclopropanamine, 2-phenyl-
• CAS NO: 54-97-7
• Molecular Formula: C₉H₁₁N
• Molecular Weight: 133.1903
• Mol File: 54-97-7.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 218.3 °C at 760 mmHg
• Flash Point: 90.8 °C
• Appearance: /
• Density: 1.065 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Phenylcyclopropane-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenylcyclopropane-1-amine(54-97-7)
• EPA Substance Registry System: 2-Phenylcyclopropane-1-amine(54-97-7)

Safety Data

• Hazardous Substances Data: 54-97-7(Hazardous Substances Data)

Usage

Uses

2-Phenylcyclopropanamine is a useful reagent for the preparation of preparation of oxadiazole derivatives as fungicides.

Upstream product

• 220247-82-5 N,N-dibenzyl-N-(2-phenylcyclopropyl)-amine 
• 155-09-9 trans-2-phenylcyclopropylamine 
• 93-92-5 1-phenylethyl acetate 
• 14561-40-1 (+/-)-cis-2-phenyl-cyclopropane-carboxylic acid-⁽¹⁾-hydrazide 
• 939-89-9 (1S*,2R*)-2-phenylcyclopropane-1-carboxylic acid 
• 874341-82-9 [(1S,2R)-2-nitrocyclopropyl]benzene 
• 100-42-5 styrene 
• 1036637-32-7 methyl (1S,2R)-1-nitro-2-phenylcyclopropanecarboxylate 
• 5685-38-1 2-phenyl-cyclopropanecarboxylic acid 
• 928054-80-2 (-)-trans-2-phenylcyclopropanecarboxylic acid (2-hydroxy-1-phenylethyl)amide 
• 4192-77-2 ethyl cinnamate 
• 946-38-3 ethyl 2-phenylcyclopropylcarboxylate 
• 1521265-16-6 (1R,2S)-2-methoxy-N-(2-phenyl-cyclopropyl)-acetamide 
• 110659-58-0 (1R,2R)-1-hydroxymethyl-2-phenylcyclopropane 

Downstream Products

• 1006-66-2 5-phenyl-4,5-dihydroisoxazole 
• 132350-68-6 (2-Nitro-cyclopropyl)-benzene 
• 65-85-0 benzoic acid 
• 1351165-22-4 C₂₁H₂₂Cl₂N₄O₂ 
• 1351165-63-3 C₂₁H₂₂Cl₂N₄O₂ 
• 1211400-41-7 (8aS)-N-(2,3-dichlorophenyl)-1,3-dioxo-2-[(1R,2S)-2-phenylcyclopropyl]hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide 
• 1351165-31-5 C₂₂H₂₅N₃O₃ 
• 1211400-32-6 (8aR)-N-(2,3-dichlorophenyl)-1,3-dioxo-2-[(1R,2S)-2-phenylcyclopropyl]hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide 
• 1351165-18-8 C₂₂H₂₅N₃O₃ 
• 50584-02-6 trans-2-Benzamido-1-phenyl-cyclopropan 
• 1521265-14-4 (2S,3S,4S)-4-fluoro-3-methoxy-2-((1R,2S)-2-phenyl-cyclopropylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Synthetic method for arylcyclopropylamine compound

The invention relates to a synthetic method for an arylcyclopropylamine compound. The method comprises the following steps: with a cinnamaldehyde compound as a raw material, reacting the cinnamaldehyde compound with bis(pinacolato)diboron to obtain a boroalkylated product; and then subjecting the boroalkylated product and an aminated compound to a ring-closure reaction so as to obtain the arylcyclopropylamine compound. Compared with the prior art, the invention has the following advantages: the synthetic method of the invention is simple to operate and short in reaction time; reagents used inthe invention are cheap and easily available; the target arylcyclopropylamine compound can be prepared from most substrates at a high overall yield and is mainly in the form of transconfiguration; anda route of the method is obviously improved, more economical, safer and easy for industrial production.

Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen

Targeting cancer with small molecule prodrugs should help overcome problems associated with conventional cancer-targeting methods. Herein, we focused on lysine-specific demethylase 1 (LSD1) to trigger the controlled release of anticancer drugs in cancer cells, where LSD1 is highly expressed. Conjugates of the LSD1 inhibitor trans-2-phenylcyclopropylamine (PCPA) were used as novel prodrugs to selectively release anticancer drugs by LSD1 inhibition. As PCPA-drug conjugate (PDC) prototypes, we designed PCPA-tamoxifen conjugates 1 a and 1 b, which released 4-hydroxytamoxifen in the presence of LSD1 in vitro. Furthermore, 1 a and 1 b inhibited the growth of breast cancer cells by the simultaneous inhibition of LSD1 and the estrogen receptor without exhibiting cytotoxicity toward normal cells. These results demonstrate that PDCs provide a useful prodrug method that may facilitate the selective release of drugs in cancer cells.